drugset
drugset / Trial / NCT05275868

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

NCT05275868 ↗

Phase 1 Terminated 41 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.

Timeline

Start
2022-10-05
Primary completion
2025-10-13
Completion
2025-10-13

Outcome

Outcome not reported

Stopped (Business): “The trial was terminated due to a business decision and not as a result of any safety concerns”

Drugs

EvaluationDrugModalityDoseRoute
Subject MGY825 Unknown — —

Indications

non-small cell lung carcinoma